Journey Medical | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 17.63 M

Revenue: As of FY2025 Q3, the actual value is USD 17.63 M, missing the estimate of USD 18.85 M.

EPS: As of FY2025 Q3, the actual value is USD -0.09.

EBIT: As of FY2025 Q3, the actual value is USD -746 K.

Segment Revenue

• Total Revenue: For the three-month period ended September 30, 2025, total revenue was $17.6 million, an increase of 21% from $14.6 million in the same period in 2024. For the nine-month period ended September 30, 2025, total revenue was $45.8 million, an increase of 8% from $42.5 million in the same period in 2024.

Operational Metrics

• Net Loss: For the three-month period ended September 30, 2025, the net loss was $2.3 million, compared to a net loss of $2.4 million in the same period in 2024. For the nine-month period ended September 30, 2025, the net loss was $10.2 million, compared to a net loss of $16.2 million in the same period in 2024.
• Operating Expenses: Total operating expenses for the three-month period ended September 30, 2025, were $19.2 million, an increase of 9% from $17.5 million in the same period in 2024. For the nine-month period ended September 30, 2025, total operating expenses were $53.5 million, a decrease of 8% from $58.4 million in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine-month period ended September 30, 2025, net cash used in operating activities was $6.2 million, compared to $11.4 million in the same period in 2024.
• Net Cash Provided by Financing Activities: For the nine-month period ended September 30, 2025, net cash provided by financing activities was $10.8 million, compared to $6.4 million in the same period in 2024.

Unique Metrics

• Product Revenue: Emrosi™ generated $4.9 million in revenue for the three-month period ended September 30, 2025, and $9.7 million for the nine-month period ended September 30, 2025, marking its commercial launch in the U.S.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue focusing on the commercialization of Emrosi™ and expanding its product portfolio through strategic acquisitions and licensing agreements. The company is also evaluating market conditions and financing alternatives to enhance its capital structure.
• Non-Core Business: The company is considering out-licensing arrangements for its products to enhance its capital structure and may seek to raise capital through debt or equity financings.